Comparing Ardent Health (NYSE:ARDT) & BioNexus Gene Lab (NASDAQ:BGLC)

Ardent Health (NYSE:ARDT) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Valuation and Earnings

This table compares Ardent Health and BioNexus Gene Lab”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardent Health	$6.32 billion	0.23	$135.81 million	$0.95	10.52
BioNexus Gene Lab	$7.43 million	0.66	-$2.98 million	($1.48)	-1.37

Ardent Health has higher revenue and earnings than BioNexus Gene Lab. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Ardent Health, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 1.9% of Ardent Health shares are owned by insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Ardent Health and BioNexus Gene Lab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ardent Health	2.09%	13.85%	4.48%
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

Volatility & Risk

Ardent Health has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 4.06, indicating that its share price is 306% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Ardent Health and BioNexus Gene Lab, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardent Health	2	5	7	0	2.36
BioNexus Gene Lab	1	0	0	0	1.00

Ardent Health currently has a consensus price target of $14.21, suggesting a potential upside of 42.15%. Given Ardent Health’s stronger consensus rating and higher probable upside, analysts plainly believe Ardent Health is more favorable than BioNexus Gene Lab.

Summary

Ardent Health beats BioNexus Gene Lab on 11 of the 14 factors compared between the two stocks.

About Ardent Health

Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.